STOCK TITAN

DSS Inc - DSS STOCK NEWS

Welcome to our dedicated news page for DSS (Ticker: DSS), a resource for investors and traders seeking the latest updates and insights on DSS.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DSS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DSS's position in the market.

Rhea-AI Summary
Impact Biomedical Inc. announces the issuance of a U.S. patent for its Laetose™ technology platform, demonstrating potential in reducing caloric intake and glycemic index in foods, while also inhibiting TNF-α, a cytokine associated with inflammatory chronic diseases. The patented formulation consists of sugars and myo-inositol, with potential applications in therapeutic administration to reduce or limit inflammatory or metabolic diseases such as diabetes. The market impact is significant, with potential applications in the US Inflammatory Disease Treatment Market, US Diabetes Treatment Market, and US Refined Sugar Production Market, all showing substantial growth projections. Impact Biomedical is accelerating discussions with potential licensing and development partners to move Laetose™ rapidly towards the market in the US and other countries worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
none
-
Rhea-AI Summary
DSS, Inc. (NYSE American: DSS) Chairman of the Board, Heng Fai Ambrose Chan, has added 672,173 shares to increase his investment in the company. This move is aimed at bolstering shareholder confidence and reflects Chairman Chan's commitment to the company's growth. CEO Frank Heuszel expressed enthusiasm for the increased stake, viewing it as a strong vote of confidence in the company's strategic direction and future potential. The company's growth trajectory, particularly evident in its wholly-owned subsidiary, DSS Securities, Inc., and Premier Packaging, signals a promising outlook for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2124.15%
Tags
acquisition
-
Rhea-AI Summary
DSS, Inc. (NYSE American: DSS) announces a 1-for-20 reverse stock split to address low price per share and maintain listing on the New York Stock Exchange American. The split will be effective on January 4, 2024, with the exact ratio to be determined by the CEO within a specified range, and trading on a post-split basis will begin on January 5, 2024. The split will not change the par value of the common stock and will affect all stockholders uniformly, except for holders of fractional shares who will receive one whole share in lieu of fractional shares. The company's transfer agent, Equiniti Trust Company, LLC, will facilitate the exchange of old stock certificates for new ones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
DSS, Inc. (DSS) announces a contract extension with Premier Packaging, its subsidiary, for a minimum of $12 Million over three years, with a potential revenue of over $15 Million including a fourth year option. The company's strategic investments in production capacity have led to increased revenues and client satisfaction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
none
-
Rhea-AI Summary
DSS, Inc. (NYSE American: DSS) announced that the Court of Appeals for the Federal Circuit (CAFC) rejected Nichia Corp.'s challenge to U.S. Patent No. 6,879,040. The CAFC upheld the 2021 Inter Partes Review decision by the USPTO Patent Trial and Appeal Board, affirming the patent's validity. DSS, Inc. plans to pursue patent infringement damages against Nichia's LED product line.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
none
-
Rhea-AI Summary
DSS Inc. (NYSE American: DSS) announced that Impact BioMedical Inc. filed a Form 8-K with the SEC, revealing a reverse stock split of its common stock by a ratio of 1 for 55. Additionally, DSS BioHealth Security, Inc. converted its common stock equity interest in Impact into Series A Convertible Preferred Stock, enhancing potential return for remaining Impact common stock equity holders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.45%
Tags
none
Rhea-AI Summary
DSS, Inc. intends to cure the stock price deficiency and return to compliance with NYSE American standards. The company received a letter from the NYSE American stating that its securities have been selling for a low price per share for a substantial period of time. The company must effect a reverse stock split or demonstrate sustained price improvement by April 20, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
none
-
Rhea-AI Summary
DSS, Inc. has filed a registration statement with the SEC for the proposed IPO of its subsidiary, Impact Biomedical, on the NYSE American exchange.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.52%
Tags
IPO offering
-
News
Rhea-AI Summary
DSS, Inc. CEO provides update on progress and expectations, highlights upcoming IPO of Impact Biomedical and growth in subsidiaries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.49%
Tags
none
Rhea-AI Summary
Jim Monaghan and Michael Cheah join DSS Wealth Management as COO and Portfolio Manager respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.82%
Tags
none
DSS Inc

NYSE:DSS

DSS Rankings

DSS Stock Data

13.04M
2.82M
59.84%
2.67%
0.2%
Computer Systems Design Services
Professional, Scientific, and Technical Services
Link
United States
West Henrietta

About DSS

dss acquires, develops and licenses innovative technologies founded on strong ip. our proprietary technologies, backed by numerous patents, are trusted by corporations, governments and financial institutions around the world. for over 25 years, dss has been a leader in anti-counterfeit, authentication, and diversion protection technologies. our custom security programs are designed to protect against product diversion, counterfeit, theft, and other costly and damaging occurrences. dss was founded to develop and commercialize important brand protection innovations, and this heritage is central to our business today. we continue to pursue innovation throughout our product divisions, and our technology management division actively invests business experience, legal expertise and capital to develop and support pioneering inventions. -follow us on twitter @docsecuritysys & @authentisuite -for more information on our authentiguard technology suite, please visit www.authentiguard.com